株式会社キュライオ

Curreio is a biotechnology platform that provides contract business for structural analysis using cryo-electron microscopy.

Based based in Tokyo, Japan, 株式会社キュライオ works in deeptech.

Profile

"Curreio is a pioneering deeptech company focused on drug discovery through the utilization of cryo-electron microscopy (Cryo-EM). Established in 2019, Curreio specializes in leveraging Cryo-EM single particle analysis to obtain precise structural information on proteins, contributing to the development of safe and effective pharmaceuticals. With a business model built on proprietary Cryo-EM technology, Curreio offers a wide range of services from protein expression to structural analysis, enabling efficient identification of novel proteins and compounds. By integrating computational chemistry and AI drug discovery, Curreio continues to advance technological developments in the field. Their innovative solution, Curreio Cryo-EM Cycle, introduces a new screening method centered around Cryo-EM, expected to be widely utilized across various drug discovery scenarios."

株式会社キュライオ is positioned in deeptech, a segment that rewards a clear, focused offering.

Its base of operations is Tokyo, Japan.

Its current recorded stage is Plug and Play portfolio startup.

Website: curreio.com